Document:

EX-4.1

 Exhibit 4.1 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
	 1.
	 	Definitions	  	 	1	 
			
	 2.
	 	Registration Rights	  	 	4	 
		 	2.1	  	Demand Registration	  	 	4	 
		 	2.2	  	Company Registration	  	 	6	 
		 	2.3	  	Underwriting Requirements	  	 	6	 
		 	2.4	  	Obligations of the Company	  	 	7	 
		 	2.5	  	Furnish Information	  	 	9	 
		 	2.6	  	Expenses of Registration	  	 	9	 
		 	2.7	  	Delay of Registration	  	 	9	 
		 	2.8	  	Indemnification	  	 	9	 
		 	2.9	  	Reports Under Exchange Act	  	 	11	 
		 	2.10	  	Limitations on Subsequent Registration Rights	  	 	12	 
		 	2.11	  	“Market Stand-off” Agreement	  	 	12	 
		 	2.12	  	Restrictions on Transfer	  	 	13	 
		 	2.13	  	Termination of Registration Rights	  	 	14	 
			
	 3.
	 	Information and Observer Rights	  	 	15	 
		 	3.1	  	Delivery of Financial Statements	  	 	15	 
		 	3.2	  	Inspection	  	 	16	 
		 	3.3	  	Termination of Information Rights	  	 	16	 
		 	3.4	  	Confidentiality	  	 	16	 
			
	 4.
	 	Rights to Future Stock Issuances	  	 	17	 
		 	4.1	  	Right of First Offer	  	 	17	 
		 	4.2	  	Termination	  	 	17	 
			
	 5.
	 	Additional Covenants	  	 	18	 
		 	5.1	  	Insurance	  	 	18	 
		 	5.2	  	Employee Agreements	  	 	18	 
		 	5.3	  	Employee Stock	  	 	18	 
		 	5.4	  	Board Matters	  	 	18	 
		 	5.5	  	Successor Indemnification	  	 	18	 
		 	5.6	  	Indemnification Matters	  	 	18	 
		 	5.8	  	Termination of Covenants	  	 	19	 
			
	 6.
	 	Miscellaneous	  	 	19	 
		 	6.1	  	Successors and Assigns	  	 	19	 
		 	6.2	  	Governing Law	  	 	20	 
		 	6.3	  	Counterparts	  	 	20	 
		 	6.4	  	Titles and Subtitles	  	 	20	 
		 	6.5	  	Notices	  	 	20	 
		 	6.6	  	Amendments and Waivers	  	 	20	 

  
 i 

									
	   
	 	6.7	  	Severability	  	 	21	 
		 	6.8	  	Aggregation of Stock	  	 	21	 
		 	6.9	  	Additional Investors	  	 	21	 
		 	6.10	  	Entire Agreement	  	 	21	 
		 	6.11	  	Dispute Resolution	  	 	21	 
		 	6.12	  	Delays or Omissions	  	 	22	 

  

					
	Schedule A	  	-	  	Schedule of Investors
	Schedule B	  	-	  	Schedule of Key Holders

  
 ii 

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of June 5, 2020, by and among
C4 Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, the stockholders set
forth on Schedule B hereto as the “Key Holders”, and any additional purchaser that becomes a party to this Agreement in accordance with Section 6.9 hereof (collectively, the “Additional
Purchasers”). 
 RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series Seed
Preferred Stock, Series A Preferred Stock, and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to that certain Investors’ Rights
Agreement dated as of December 29, 2015, by and among the Company and such Existing Investors (the “Prior Agreement”); and 

WHEREAS, the Existing Investors are holders of a majority of the Registrable Securities of the Company (as defined in the Prior
Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; 

WHEREAS, certain of the Investors are parties to that certain Series B Preferred Stock Purchase Agreement of even date herewith
by and among the Company and such Investors (the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement by such
Investors, Existing Investors holding a majority of the Registrable Securities, and the Company; and 
 WHEREAS, Perceptive Credit
Holdings III, LP holds a warrant to purchase shares of Series B Preferred Stock issued pursuant to that certain Warrant Certificate of even date herewith (the “Warrant”) and is deemed an Investor hereunder; 

NOW, THEREFORE, the Existing Investors hereby agree that the Prior Agreement shall be amended and restated in its entirety, and
the parties to this Agreement further agree as follows: 
 1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, (i) with respect to any specified Person, any other 

Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner,
managing member, officer or director of such Person or any venture capital, private equity or other investment fund now or hereafter existing that is controlled by one or more general partners or managing members or investment advisors of, or shares
the same management company or investment advisor with, such Person; and (ii) with respect to a natural Person, any Immediate Family Member of such Person and any trust for the benefit of a such Person. 

 1.2 “Common Stock” means shares of the Company’s common stock, par
value $0.0001 per share. 
 1.3 “Damages” means any loss, damage, claim or liability (joint or several) to which a party
hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or
alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged
omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of
the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.4 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.5 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.6 “Excluded
Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145
transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration
in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.7 “Form S-1” means such form under the Securities Act as in effect on the date
hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.8 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 
 1.9 “GAAP” means generally accepted
accounting principles in the United States. 
 1.10 “Holder” means any holder of Registrable Securities who is a party to
this Agreement. 
 1.11 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, sibling, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

  
 2 

 1.12 “Initiating Holders” means, collectively, Holders who properly
initiate a registration request under this Agreement. 
 1.13 “IPO” means the Company’s first underwritten public
offering of its Common Stock under the Securities Act. 
 1.14 “Key Employee” means any executive-level employee
(including, division director and vice president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

1.15 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least
1,419,824 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.16 “Major Holder” means any Investor and the Key Holders. 

1.17 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.18 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.19 “Preferred Stock” means shares of the Company’s Series B Preferred Stock, Series A Preferred Stock, and Series
Seed Preferred Stock. 
 1.20 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion
of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors on or after the date
hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the
shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to
Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.21 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities, other than the shares of
Common Stock issuable (directly or indirectly) upon the exercise of the Warrant. 

  
 3 

 1.22 “Restricted Securities” means the securities of the Company required
to be notated with the legend set forth in Subsection 2.12(b) hereof. 
 1.23 “SEC” means the Securities and
Exchange Commission. 
 1.24 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.25 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.26 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.27 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

1.28 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0005 per share.

 1.29 “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0005 per
share. 
 1.30 “Series Seed Preferred Stock” means shares of the Company’s Series Seed Preferred Stock, par value
$0.0005 per share. 
 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) two (2) years after the date
of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Investors holding at least forty percent (40%) percent of Preferred Stock then
outstanding that the Company file a Form S-1 registration statement with respect to at least twenty-five percent (25%) of the Registrable Securities then outstanding or a lesser percent if the anticipated
aggregate offering price would exceed $10 million, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the
Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement
under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice
given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

  
 4 

 (b) Form S-3 Demand. If at any time when it
is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty percent (20%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3 million, then the Company
shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the
date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any
other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection
2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for such registration
statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate
reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company
unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be
tolled correspondingly, for a period of not more than an aggregate of ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company shall not register any securities for its own account or that of
any other stockholder during such ninety (90) day period other than an Excluded Registration. 
 (d) The Company shall not be obligated
to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is
one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become
effective; (ii) after the Company has effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection
2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated
registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to
Subsection 2.1(b) within the twelve (12) month period immediately 

  
 5 

 preceding the date of such request. A registration shall not be counted as “effected” for purposes
of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses
therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d).

 2.2 Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company
for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly
give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered
all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2(b) before the
effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance
with Subsection 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and
shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the managing
underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would
be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the
Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the
underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

  
 6 

 (b) In connection with any offering involving an underwriting of shares of the
Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon
between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable
Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success
of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among
the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation
of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the
number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities
included in the offering be reduced below twenty percent (20%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the
determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited
liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired
members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of
Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 
 2.4 Obligations
of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period
of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of
Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be
extended for up to ninety (90) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

  
 7 

 (b) prepare and file with the SEC such amendments and supplements to such registration
statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available for
inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

  
 8 

 (j) after such registration statement becomes effective, notify each selling Holder of any
request by the SEC that the Company amend or supplement such registration statement or prospectus. 
 In addition, the Company shall ensure
that, at all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may
implement a trading program under Rule 10b5-1 of the Exchange Act. 
 2.5 Furnish
Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall
furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable
Securities. 
 2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations,
filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees
and disbursements of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any
registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall
bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration
pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the
Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit
their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders
pro rata on the basis of the number of Registrable Securities registered on their behalf. 
 2.7 Delay of Registration. No Holder
shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
Section 2. 
 2.8 Indemnification. If any Registrable Securities are included in a registration statement
under this Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each
selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as 

  
 9 

 defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or
underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably
incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(a)
shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to
the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person
expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each selling Holder, severally and not
jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel
and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each
case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages
may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is
effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections
2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any
governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying
party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been
given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one
counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due
to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the 

  
 10 

 commencement of any such action shall relieve such indemnifying party of any liability to the indemnified
party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that
it may have to any indemnified party otherwise than under this Subsection 2.8. 
 (d) To provide for just and equitable contribution
to joint liability under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by
the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that
this Subsection 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then,
and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault
of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable
considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged
omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or
omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such
registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent
misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the
proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this
Agreement. 

  
 11 

 2.9 Reports Under Exchange Act. With a view to making available to the Holders the
benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company shall: 
 (a) make and keep available adequate current public information, as those
terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form
S-3 (at any time after the Company so qualifies to use such form). 
 2.10 Limitations on
Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the holders of a majority of the shares of Preferred Stock then outstanding, enter into any agreement with any
holder or prospective holder of any securities of the Company that (i) would provide to such holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a
subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities that they wish to so include; provided that this limitation shall not apply to any additional
Investor who becomes a party to this Agreement in accordance with Subsection 6.9. 
 2.11 “Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to
the registration by the Company of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1 or Form
S-3, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the IPO), or such other period as may be requested
by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions
contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant
any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities 

  
 12 

 convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock (whether such
shares or any such securities are then owned by the Holder or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such
securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall only apply to
the IPO unless an Affiliate or other representative of the Holder is member of the Company’s Board of Directors at the time of the commencement of the foregoing period, and shall not apply to the sale of any shares to an underwriter pursuant to
an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the
restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions. The
underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder
further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto. 

2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate, instrument, or book entry representing (i) the
Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or
similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

  
 13 

 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall
give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the
effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or
transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the
terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such
Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book
entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such
certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities
Act. 
 2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable
Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 
 (a) the
closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation; 
 (b) such time as Rule
144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and 

(c) the fifth anniversary of the IPO. 

  
 14 

 3. Information Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors has
not reasonably determined that such Major Investor is a competitor of the Company: 
 (a) as soon as practicable, but in any event within
one hundred eighty (180) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’
equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the four (4) quarters of each
fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may
(i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement for such
month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and
(ii) not contain all notes thereto that may be required in accordance with GAAP); 
 (d) as soon as practicable, but in any event
thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), prepared on a monthly basis, including balance sheets, income statements, and statements of
cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; and 
 (e) such other
information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under
this Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the
Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this
Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules
applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially
reasonable efforts to cause such registration statement to become effective. 

  
 15 

 3.2 Inspection. The Company shall permit each Major Investor (provided that
the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and
discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated
pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form
acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Termination of Information Rights. The covenants set forth in Subsection 3.1 and Subsection 3.2 shall terminate and
be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon
a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 
 3.4
Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the
Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a
result of a breach of this Subsection 3.4 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or
disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its
attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such
Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.4; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary
course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law,
regulation, rule, court order or subpoena, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

  
 16 

 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Holder. A Major Holder shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems
appropriate, among itself and its Affiliates. 
 (a) The Company shall give notice (the “Offer Notice”) to each Major
Holder, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Holder may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Holder (including all shares of Common Stock then
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Holder) bears to the total Common Stock of the Company then outstanding (assuming
full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date that the
Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 
 (c) If all New Securities
referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection
4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does
not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New
Securities shall not be offered unless first reoffered to the Major Holders in accordance with this Subsection 4.1. 
 (d) The right
of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Company’s Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of
shares of Series B Preferred Stock to Additional Purchasers (as defined in the Purchase Agreement). 
 4.2 Termination. The covenants
set forth in Subsection 4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of the Qualified Public Offering (as defined in the Company’s Certificate of Incorporation), (ii) when the
Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event (as defined in the Company’s Certificate of Incorporation), whichever event
occurs first. 

  
 17 

 5. Additional Covenants. 

5.1 Insurance. The Company shall use its commercially reasonable efforts to obtain, within ninety (90) days of the date hereof,
from financially sound and reputable insurers Directors and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board of Directors, and will use commercially reasonable efforts to cause such insurance policies
to be maintained until such time as the Board of Directors determines that such insurance should be discontinued. 
 5.2 Employee
Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or
trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and (ii) each Key Employee to enter into a nonsolicitation agreement, substantially in the form approved by the Board of Directors. In addition, the
Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of the Board of Directors.

 5.3 Employee Stock. Unless otherwise approved by the Board of Directors, all future employees and consultants of the Company who
purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares
over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following
thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in Subsection 2.11. In addition, unless otherwise approved
by the Board of Directors, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of
restricted stock. 
 5.4 Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the
Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable
out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. 

5.5 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with
respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may
be. 

  
 18 

 5.6 Indemnification Matters. The Company hereby acknowledges that one (1) or
more of the directors nominated to serve on the Board of Directors by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the
Investors and certain of their Affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Fund Director are primary and
any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses
incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the
Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c) that it
irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no
advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a
right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 

5.7 Termination of Covenants. The covenants set forth in this Section 5, except for Subsection 5.7,
shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act,
or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 

6. Miscellaneous. 
 6.1
Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that(i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate
Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least twenty-five (25%) of such Holder’s Registrable Securities (subject
to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of
the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms
and conditions of this Agreement, including the provisions of Subsection 2.11; and (z) such transferee qualifies as an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. For
the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or
(3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify
individually for assignment of rights shall have a single attorney-in-fact for 

  
 19 

 the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The
terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement shall be governed by the internal law of the State of Delaware, without regard to conflict of law
principles that would result in the application of any law other than the law of the State of Delaware. 
 6.3 Counterparts. This
Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail
(including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered
and be valid and effective for all purposes. 
 6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are
for convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.5 Notices. All notices and other
communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by
electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day
delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A or Schedule B (as applicable) hereto, or to the principal office of the Company
and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is
given to the Company, a copy shall also be sent to Lawrence S. Wittenberg, Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02110. 

6.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding; provided that the Company may
in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to
be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or
terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or 

  
 20 

 waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of
Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by
agreement with the Company, purchase securities in such transaction). Further, Section 4 of this Agreement may not be amended, and no provision thereof may be waived, in each case, in any way which would adversely affect the rights of the Key
Holders thereunder in a manner disproportionate to any adverse effect such amendment or waiver would have on the rights of the Investors thereunder, without also the written consent of the Key Holders. Company shall give prompt notice of any
amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be
binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a
further or continuing waiver of any such term, condition, or provision. 
 6.7 Severability. In case any one or more of the
provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal,
or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the
Company’s Series B Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Series B Preferred Stock may become a party to this Agreement by executing and delivering an
additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional
Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the
Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of
the Commonwealth of Massachusetts and to the jurisdiction of the United States District Court for the District of Massachusetts for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not
to 

  
 21 

 commence any suit, action or other proceeding arising out of or based upon this Agreement except in the
state courts of the Commonwealth of Massachusetts or the United States District Court for the District of Massachusetts, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or
proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that
the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE
OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT
RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH
OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.12 Delays or Omissions. No delay or omission to exercise
any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be
construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore
or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

[Remainder of Page Intentionally Left Blank] 

  
 22 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	C4 THERAPEUTICS, INC.
		
	By:	 	 /s/ Marc Cohen

		 	Name: Marc Cohen
		 	Title: Chief Executive Officer

 SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	T. Rowe Price Health Sciences Fund, Inc.
	TD Mutual Funds – TD Health Sciences Fund
	VALIC Company I – Health Sciences Fund
	T. Rowe Price Health Sciences Portfolio
	Each account, severally and not jointly
	
	By: T. Rowe Price Associates, Inc., Investment
	Adviser or Subadviser, as applicable
		
	By:	 	 /s/ Andrew Baek

	Name: Andrew Baek
	Title: Vice President

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ADAGE CAPITAL PARTNERS, LP
	
	By: Adage Capital Partners, GP, LLC, its General Partner
	
	By: Adage Capital Advisors, LLC, its Managing Member
		
	By:	 	 /s/ Dan Lehan

	Name: Dan Lehan
	Title: Chief Operating Officer

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	AXIL LIFE SCIENCE & HEALTHCARE
	FUND I INVESTMENT LIMITED
	PARTNERSHIP
	
	ITS GENERAL PARTNER, AXIL CAPITAL
	PARTNERS LLP
		
	By:	 	 /s/ Frederick Shane

	Name: Frederick Shane
	Title: Managing Partner

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BAIN CAPITAL LIFE SCIENCES FUND II, L.P.
	
	 By: Bain Capital Life Sciences Investors II, LLC

its general partner

	
	 By: Bain Capital Life Sciences Investors, LLC

its manager

		
	By:	 	 /s/ Andrew Hack

	Name: Andrew Hack
	Title: Managing Director

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BC DYNAMOPHARM LIMITED
		
	By:	 	 /s/ Qianye Karen Liu

	Name: Qianye Karen Liu
	Title: Director

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BCIP LIFE SCIENCES ASSOCIATES, L.P.
	
	 By: Boylston Coinvestors, LLC
 its
general partner

		
	By:	 	 /s/ Andrew Hack

	Name: Andrew Hack
	Title: Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BLACKWELL PARTNERS LLC – SERIES A
		
	By:	 	 /s/ Abayomi A. Adigun

	Name: Abayomi A. Adigun
	Title: Investment Manager
	          DUMAC, Inc., Authorized Signatory
		
	By:	 	 /s/ Jannine M. Lall

	Name: Jannine M. Lall
	Title: Head of Finance & Controller
	          DUMAC, Inc., Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	COBRO VENTURES OPPORTUNITY FUND, L.P.
		
	By:	 	 /s/ Todd Kaloudis

	Name:	 	Todd Kaloudis
	Title:	 	Managing Member of Cobro Opportunity
		 	Fund GP, LLC, General Partner

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	COMMODORE CAPITAL MASTER LP
		
	By:	 	 /s/ Michael Kramarz, MD

	Name: Michael Kramarz, MD
	Title: Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	DREW O’CONNOR DENNISON
	REVOCABLE TRUST DATED DECEMBER 12, 2016
		
	By:	 	 /s/ Drew O’Connor Dennison

	Name: Drew O’Connor Dennison
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Geoffrey Meyerson

	Geoffrey Meyerson

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	HBM HEALTHCARE INVESTMENTS
	(CAYMAN) LTD.
		
	By:	 	 /s/ Jean-Marc LeSieur

	Name: Jean-Marc LeSieur
	Title: Managing Director

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	JANUS HENDERSON BIOTECH
	INNOVATION MASTER FUND LIMITED
	
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

	Name: Andrew Acker
	Title: Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	JANUS HENDERSON CAPITAL FUNDS PLC
	ON BEHALF OF ITS SERIES JANUS
	HENDERSON GLOBAL LIFE SCIENCES
	FUND
	
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

	Name: Andrew Acker
	Title: Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	JANUS HENDERSON GLOBAL LIFE SCIENCES FUND
	
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

	Name: Andrew Acker
	Title: Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	JANUS HENDERSON HORIZON FUND-BIOTECHNOLOGY FUND
	
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

	Name: Andrew Acker
	Title: Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	LC CURIOSITY LLC
		
	By:	 	 /s/ Rodger O. Riney

	Name: Rodger O. Riney
	Title: Managing Member

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	LOGOS OPPORTUNITIES FUND II, L.P.
	
	By: Logos Opportunities GP, LLC
	Its General Partner
		
	By:	 	 /s/ Graham Walmsley

	Name: Graham Walmsley
	Title: Manager

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	MIZUHO SECURITIES PRINCIPAL
	INVESTMENT CO., LTD.
		
	By:	 	 /s/ Ryota Suzuki

	Name: Ryota Suzuki
	Title: President & CEO

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	NEXTECH VI ONCOLOGY SCSP
	
	Nextech VI GP S.à r.l. as General Partner on behalf  of Nextech VI Oncology SCSp’
		
	By:	 	 /s/ James Pledger

	Name: James Pledger
	Title: Manager

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD
		
	By:	 	 /s/ James H. Mannix

	Name: James H. Mannix
	Title: Chief Operating Officer

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	RA CAPITAL HEALTHCARE FUND, L.P.
	
	By: RA Capital Healthcare Fund GP, LLC
Its General Partner
		
	By:	 	 /s/ Peter Kolchinsky

	Name: Peter Kolchinsky
	Title: Manager

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	RA CAPITAL NEXUS FUND, L.P.
	
	 By: RA Capital Nexus Fund GP, LLC

Its: General Partner

		
	By:	 	 /s/ Peter Kolchinsky

	Name: Peter Kolchinsky
	Title: Manager

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	RTW INNOVATION MASTER FUND, LTD.
		
	By:	 	 /s/ Roderick Wong, M.D.

	Name: Roderick Wong, M.D.
	Title: Director

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	RTW MASTER FUND, LTD.
		
	By:	 	 /s/ Roderick Wong, M.D.

	Name: Roderick Wong, M.D.
	Title: Director

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	RTW VENTURE FUND LIMITED
	
	By: RTW Investments, LP, its Investment Manager
		
	By:	 	 /s/ Roderick Wong, M.D.

	Name: Roderick Wong, M.D.
	Title: Managing Partner

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SPHERA BIOTECH MASTER FUND L.P.
		
	By:	 	 /s/ Doron Breen

	Name: Doron Breen
	Title: Portfolio Manager

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SUPERSTRING CAPITAL MASTER FUND LP
		
	By:	 	 /s/ Ting Guo

	Name: Ting Guo
	Title: Partner

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 TAIWANIA CAPITAL BUFFALO II

BIOVENTURES, LP

	
	By its investment manager, Taiwania Capital Management Corporation
		
	By:	 	 /s/ Jerome Shen, PhD

	Name: Jerome Shen, PhD
	Title: General Partner, Bio Fund

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	WYANDANCH PARTNERS, L.P.
		
	By:	 	 /s/ Keith R. Gollust

	By: Keith R. Gollust
	President, Gollust Management, Inc.
	General Partner Wyandanch Partners, L.P.

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	YONGLI (CAYMAN) LIMITED
		
	By:	 	 /s/ Ni Wenjie

	Name: Ni Wenjie
	Title: Director

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	YONJIN VENTURE LLC
		
	By:	 	 /s/ Wang Daguang

	Name: Wang Daguang
	Title: Director

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	A. Robert Zeff Revocable Trust
		
	By:	 	 /s/ A. Robert Zeff

	Name: A. Robert Zeff
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Alan Stone

	Alan Stone

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Alexander Keith Stewart

	Alexander Keith Stewart

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Bruce Downey

	Bruce Downey

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 CYNTHIA E. ANDERSON 2015

IRREVOCABLE TRUST DATED AUGUST 10, 2015

		
	By:	 	 /s/ Cynthia E. Anderson

	Name: Cynthia E. Anderson
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	DF Investment Partners LLC
		
	By:	 	 /s/ Glenn Dubin

	Name:	 	Glenn Dubin
	Title:	 	Managing Member

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Dharminder Chauhan

	Dharminder Chauhan
	
	 /s/ Reetu Chauhan

	Reetu Chauhan

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Don Brown

	Don Brown

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Evan Andrew Knisely

	Evan Knisely

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Evan Andrew Knisely Trust u/a dtd 10/13/2017
		
	By:	 	 /s/ Evan Andrew Knisely

	Name:	 	Evan Andrew Knisely
	Title:	 	Co-Trustee
		
	By:	 	 /s/ Trisha Nicole Arteaga Knisely

	Name:	 	Trisha Nicole Arteaga Knisely
	Title:	 	Co-Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Gus Kaloudis

	Gus Kaloudis

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Herman Cohen

	Herman Cohen
	
	 /s/ Suzanne Cohen

	Suzanne Cohen

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Jason Fisherman

	Jason Fisherman

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	KENNETH C. ANDERSON 2015
	IRREVOCABLE TRUST DATED AUGUST 10, 2015
		
	By:	 	 /s/ David Anderson

	Name:	 	David Anderson
	Title:	 	Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Kirk Ott

	Kirk Ott

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Malcolm Salter

	Malcolm Salter

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	MC4, LLC
		
	By:	 	 /s/ Arthur Becker

	Name:	 	Arthur Becker
	Title:	 	Managing Member

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Mike Smith

	Mike Smith

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Nikhil Munshi

	Nikhil Munshi

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Peter Rukeyser

	Peter Rukeyser

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Philip W. McCarty

	Philip W. McCarty

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Pierre Rovani

	Pierre Rovani

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Rama Elluru

	Rama Elluru

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Steven Allen

	Steven Allen

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Teru Hideshima

	Teru Hideshima

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Wakara Healthcare Investments, LLC
		
	By:	 	 /s/ John Malooly

	Name: John Malooly
	Title: Managing Partner

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	2014 Exchange Place Fund A, LLC
		
	By:	 	 /s/ David Henken

	Name: David Henken
	Title: Manager

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	2014 Exchange Place Fund B, LLC
		
	By:	 	 /s/ David Henken

	Name: David Henken
	Title: Manager

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Alain Cohen

	Alain Cohen

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Alex Williams

	Alex Williams

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Amy Digeso.

	Amy Digeso.
	
	 /s/ Paul Rakowski, Sr.

	Paul Rakowski, Sr.

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Beach Trust
		
	By:	 	 /s/ Marcie Stuchin

	Name: Marcie Stuchin
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Marcie Stuchin

	Marcie Stuchin

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Berenice Ronthal

	Berenice Ronthal
	
	 /s/ Michael Ronthal

	Michael Ronthal

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	C4Ever, LLC
		
	By:	 	 /s/ Sara Mokhtari

	Name: Sara Mokhtari
	Title: Managing Member

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Carol Nakhuda

	Carol Nakhuda

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Cormorant Global Healthcare Master Fund, LP
		
	By:	 	 /s/ Bihua Chen

	Name: Bihua Chen
	Title: Managing Member of GP

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Cormorant Private Healthcare Fund 1, LP
		
	By:	 	 /s/ Bihua Chen

	Name: Bihua Chen
	Title: Managing Member of GP

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CRMA SPV, L.P.
	
	By: Cormorant Asset Management, LLC, its Attorney-in-Fact
		
	By:	 	 /s/ Bihua Chen

	Name: Bihua Chen
	Title: Managing Member of GP

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Cynthia E. Anderson 2016 Grantor Retained Annuity Trust
		
	By:	 	 /s/ Cynthia E. Anderson

	Name: Cynthia E. Anderson
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Cynthia Anderson

	Cynthia Anderson

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Elizabeth Klein

	Elizabeth Klein

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ERP Business Holdings, LP
		
	By:	 	 /s/ Elena Prokupets

	Name: Elena Prokupets
	Title: General Partner

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Evan Knisely

	Evan Knisely

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Evan Andrew Knisely Trust u/a dtd 10/13/2017
		
	By:	 	 /s/ Evan Andrew Knisely

	Name: Evan Andrew Knisely
	Title: Co-Trustee
		
	By:	 	 /s/ Trisha Nicole Arteaga Knisely

	Name: Trisha Nicole Arteaga Knisely
	Title: Co-Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Evans Investment Management, LLC
		
	By:	 	 /s/ Bruce Evans

	Name: Bruce Evans
	Title: Managing Member

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Francis Rhoads

	Francis Rhoads

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Gracie Partners LLC
		
	By:	 	 /s/ David R. Salomon

	Name: David R. Salomon
	Title: Managing Member

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Greg Phelps

	Greg Phelps

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	 Kenneth C. Anderson 2016 Grantor Retained

Annuity Trust

		
	By:	 	 /s/ Kenneth C. Anderson

	Name: Kenneth C. Anderson
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Kenneth C. Anderson

	Kenneth C. Anderson

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Lawrence S. Wittenberg

	Lawrence S. Wittenberg and Barbara J. Kane
	JTWROS
	
	 /s/ Barbara J. Kane

	Lawrence S. Wittenberg and Barbara J. Kane
	JTWROS

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Lisa Popitz

	Lisa Popitz

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Lori Alf

	Lori Alf

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Marc Grenouilleau

	Marc Grenouilleau

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Novartis Institutes for Biomedical Research, Inc.
		
	By:	 	 /s/ Scott Brown

	Name: Scott Brown
	Title: Vice President and General Counsel

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Paul Anderson

	Paul Anderson

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Roger K. Taylor Preservation Trust Agreement
		
	By:	 	 /s/ Jerry B. McQueen

	Name: Jerry B. McQueen
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Ronald W. Kaiser

	Ronald W. Kaiser and Teresa Kaiser JTWROS
	
	 /s/ Teresa Kaiser

	Ronald W. Kaiser and Teresa Kaiser JTWROS

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Schermerhorn 2012 Dynasty Trust
		
	By:	 	 /s/ Miriam Esteve

	Name: Miriam Esteve
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Stephen Brown

	Stephen Brown

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Susan Korsmeyer

	Susan Korsmeyer

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	The John F. W. Rogers 2008 Family Trust
		
	By:	 	 /s/ Deborah Lehr

	Name: Deborah Lehr
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	The Paula Berliner Revocable Trust dated May 3, 2016, as amended and restated
		
	By:	 	 /s/ Deborah Reiss

	Name: Deborah Reiss
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	WCS, Jr. 2012 Family Trust
		
	By:	 	 /s/ Rebecca L. Sanders

	Name: Rebecca L. Sanders
	Title: Trustee

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ Marc Cohen

	Marc Cohen

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Celgene Rivot LLC
		
	By:	 	 /s/ Daniel O’Connell

	Name: Daniel O’Connell
	Title: Officer

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	 /s/ John Rogers

	John Rogers

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Roche Finance Ltd
		
	By:	 	 /s/ Carole Nuechterlein

	Name: Carole Nuechterlein
	Title: Authorized Signatory
		
	By:	 	 /s/ Beat Krähenmann

	Name: Beat Krähenmann
	Title: Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PERCEPTIVE CREDIT HOLDINGS III, LP
	
	By: Perceptive Credit Opportunities GP, LLC, its general partner
		
	By:	 	 /s/ Sandeep Dixit

	Name: Sandeep Dixit
	Title: Chief Credit Officer
		
	By:	 	 /s/ Sam Chawla

	Name: Sam Chawla
	Title: Portfolio Manager

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	KEY HOLDER:
	
	Dana Farber Cancer Institute, Inc.
		
	By:	 	 /s/ Melissa J. Chammas

	Name: Melissa J. Chammas
	Title: Senior Director of Financial Operations

 SCHEDULE A 

Investors 
 Name and Address

 Cobro Ventures Opportunity Fund, L.P. 
 1000
Wilson Blvd. #1800 
 Arlington, VA 22209 
 LC Curiosity LLC

 P.O. Box 31729 
 St. Louis, MO 63131 

Attn: Rodger Riney, Managing Member 
 Drew O’Connor
Dennison Revocable Trust dated December 12, 2016 
 2 Bellerive Country Club Grounds Drive St. Louis, MO 63141 

Attn: Drew O’Connor Dennison, Trustee 
 Geoffrey Meyerson

 88 Woodbine Circle 
 Needham, MA 02494 

Yongli (Cayman) Limited (1) 
 Governors Square, Suite#5-204 
 23 Lime Tree Bay Avenue 

P.O.Box 2547 
 Grand Cayman,
KYI-1104 
 Cayman Islands 

Superstring Capital Master Fund LP 
 150 E 52nd St, Suite
5004 
 New York, NY, 10022 
 Yonjin Venture LLC 

3500 South DuPont Highway 
 Dover, County of Kent, DE 19901 

Taiwania Capital Buffalo II Bioventures, LP 
 Rm 1806,
18th Floor, No. 333, Sec.1, Keelung Rd. 
 Xinyi District, Taipei City, Taiwan 11012 

Axil Life Science & HealthCare Fund I Investment, L.P. 

c/o Axil Capital Partners LLP 
 Nihonbashi Life Science Building 2

 11-5, Nihonbashi -honcho 3-chome
Chuo-ku, Tokyo, Japan 

 BC DynamoPharm Limited 

Trinity Chambers, PO Box 4301, Road Town, Tortola, British Virgin Islands 

With a copy for notice: 
 Suite 701, Tower C, Tsinghua Science
Park, No. 1 Zhongguancun East Road, Haidian District 
 Beijing, 100084, China 

Attn: Qianye Karen Liu 
 Email: karen.liu@3ebio.com 

Mizuho Securities Principal Investment Co., Ltd. 

Ochanomizu First Bldg. 10F 
 2-5-1 Kandasurugadai, Chiyoda-ku Tokyo 101-0062, Japan 

Wyandanch Partners, L.P. 
 645 Madison Avenue 

20th Floor 
 New York, NY 10022 

Attn: Keith R Gollust 
 Perceptive Life Sciences Master Fund
LTD. 
 51 Astor Place 10th Floor 
 New York, NY 10003 

Attn: Adam Stone 
 Adage Capital Partners, LP 

200 Clarendon Street, Floor 52 
 Boston, MA 02116 

BCIP Life Sciences Associates, L.P. 
 200 Clarendon Street

 Boston, MA 02116 
 Attn: Andrew Hack 

Bain Capital Life Sciences Fund II, L.P. 
 200 Clarendon
Street 
 Boston, MA 02116 
 Attn: Andrew Hack 

Commodore Capital Master LP 
 c/o Commodore Capital LP

 55 Hudson Yards, Fl. 29 
 New York, NY 10001 

HBM Healthcare Investments (Cayman) Ltd. 
 Governors
Square, Suite #4-212-2 
 23 Lime Tree Bay Avenue 

PO Box 30852 
 Grand Cayman,
KY1-9006, Cayman Islands 
 Tel: ++1.345.946.8002 

Fax: ++1.345.946.8003 

 Janus Henderson Global Life Sciences Fund 

c/o Janus Capital Management LLC 
 151 Detroit Street 

Denver, CO 80206 
 Attention: Andy Acker and Angela Morton 

Email: Andy.Acker@JanusHenderson.com; Angela.Morton@JanusHenderson.com 

With a copy (which shall not constitute notice) to: Adrian Rich 

Perkins Coie LLP 
 3150 Porter Drive Palo Alto, CA 94306 

Email: arich@perkinscoie.com 
 Janus Henderson Capital
Funds plc - Janus Henderson Global Life Sciences Fund 
 c/o Janus Capital Management LLC 

151 Detroit Street 
 Denver, CO 80206 

Attention: Andy Acker and Angela Morton 
 Email:
Andy.Acker@JanusHenderson.com; Angela.Morton@JanusHenderson.com 
 With a copy (which shall not constitute notice) to: 

Adrian Rich 
 Perkins Coie LLP 

3150 Porter Drive Palo Alto, CA 94306 
 Email:
arich@perkinscoie.com 
 Janus Henderson Biotech Innovation Master Fund Limited 

c/o Janus Capital Management LLC, 
 151 Detroit Street 

Denver, CO 80206 
 Attention: Andy Acker and Angela Morton 

Email: Andy.Acker@JanusHenderson.com; Angela.Morton@JanusHenderson.com 

With a copy (which shall not constitute notice) to: Adrian Rich 

Perkins Coie LLP 
 3150 Porter Drive Palo Alto, CA 94306 

Email: arich@perkinscoie.com 
 Janus Henderson Horizon
Fund-Biotechnology Fund 
 c/o Janus Capital Management LLC 

151 Detroit Street 
 Denver, CO 80206 

Attention: Andy Acker and Angela Morton 
 Email:
Andy.Acker@JanusHenderson.com; Angela.Morton@JanusHenderson.com 

 With a copy (which shall not constitute notice) to: 

Adrian Rich 
 Perkins Coie LLP 

3150 Porter Drive Palo Alto, CA 94306 
 Email:
arich@perkinscoie.com 
 Logos Opportunities Fund II, L.P. 

1 Letterman Drive 
 Building D, Suite D3-700 
 San Francisco, CA 94129 

Nextech VI Oncology SCSP 
 8 rue Lou Hemmer L-1748 Senningerberg 
 Grand Duchy of Luxembourg 

RA Capital Healthcare Fund, L.P. 
 c/o RA Capital
Management, L.P. 
 200 Berkeley Street 
 18th Floor Boston, MA
02116 
 Attn: General Counsel 
 Blackwell Partners LLC
– Series A 
 280 S. Mangum Street 
 Suite 210 

Durham, NC 27701 
 Attn: Jannine Lall 

RA Capital Nexus Fund, L.P. 
 c/o RA Capital Management,
L.P. 
 200 Berkeley Street 
 18th Floor Boston, MA 02116 

Attn: General Counsel 
 RTW Master Fund, Ltd. 

c/o RTW Investments, LP 
 412 West 15th Street, Floor 9 

New York, NY 10011 
 With a copy (which shall not constitute
notice) to: 
 Ryan A. Murr 
 Gibson, Dunn & Crutcher
LLP 
 555 Mission Street, San Francisco, CA 94105-0921 
 Fax:
+1 415.374.8430 
 Email: rmurr@gibsondunn.com 

 RTW Innovation Master Fund, Ltd 

c/o RTW Investments, LP 
 412 West 15th Street, Floor 9 

New York, NY 10011 
 With a copy (which shall not constitute
notice) to: 
 Ryan A. Murr 
 Gibson, Dunn & Crutcher
LLP 
 555 Mission Street, San Francisco, CA 94105-0921 
 Fax:
+1 415.374.8430 
 Email: rmurr@gibsondunn.com 
 RTW
Venture Fund Limited 
 c/o RTW Investments, LP 412 West 15th Street, Floor 9 

New York, NY 10011 
 With a copy (which shall not constitute
notice) to: 
 Ryan A. Murr 
 Gibson, Dunn & Crutcher
LLP 
 555 Mission Street, San Francisco, CA 94105-0921 
 Fax:
+1 415.374.8430 
 Email: rmurr@gibsondunn.com 

Sphera Biotech Master Fund L.P. c/o Maples Corporate Services Limited P.O. Box 309 

Ugland House, Grand Cayman KY1-1104 Cayman Islands 

T. Rowe Price Health Sciences Fund, Inc. 
 c/o T. Rowe
Price Associates, Inc. 
 100 East Pratt Street 
 Baltimore, MD
21202 
 Attn: Andrew Baek, Vice President 
 TD Mutual Funds
– TD Health Sciences Fund 
 c/o T. Rowe Price Associates, Inc. 

100 East Pratt Street 
 Baltimore, MD 21202 

Attn: Andrew Baek, Vice President 
 VALIC Company I –
Health Sciences Fund 
 c/o T. Rowe Price Associates, Inc. 

100 East Pratt Street 
 Baltimore, MD 21202 

Attn: Andrew Baek, Vice President 

 T. Rowe Price Health Sciences Portfolio 

c/o T. Rowe Price Associates, Inc. 
 100 East Pratt Street 

Baltimore, MD 21202 
 Attn: Andrew Baek, Vice President 

Perceptive Credit Holdings III, LP 
 c/o Perceptive
Advisors LLC 
 51 Astor Place, 10th Floor New York, NY 10003 

Attention:    Sandeep Dixit 
 E-mail: Sandeep@perceptivelife.com 
 with a copy to: 

Chapman and Cutler LLP 
 1270 Avenue of the Americas 

New York, NY 10020 
 Attention: Nicholas Whitney 

whitney@chapman.com 
 Marc Cohen 

6455 Kedleston Court 
 McLean, VA 22101 

Alain Cohen 
 181 Chain Bridge Rd. 

McLean, VA 22101 
 Cormorant Private Healthcare Fund I, LP

 200 Clarendon Street, 52nd Floor 
 Boston, MA 02116 

Attention: Bihua Chen 
 Cormorant Global Healthcare Master
Fund, LP 
 200 Clarendon Street, 52nd Floor 
 Boston, MA
02116 
 Attention: Bihua Chen 
 CRMA SPV, L.P. 

P.O. Box 309, Ugland House 
 Grand Cayman, KY1-1104 
 Cayman Islands 

KPC Venture Capital LLC 
 C/O The Kraft Group 

One Patriot Place 
 Foxborough, MA 02035 

Attention: Bill Scalzulli 

 JAK II LLC 

C/O The Kraft Group 
 One Patriot Place 

Foxborough, MA 02035 
 Attention: Bill Scalzulli 

TWO R LLC 
 C/O The Kraft Group 

One Patriot Place 
 Foxborough, MA 02035 

Attention: Bill Scalzulli 
 Daniel A. Kraft 

C/O The Kraft Group 
 One Patriot Place 

Foxborough, MA 02035 
 Attention: Bill Scalzulli 

Joshua M. Kraft 
 C/O The Kraft Group 

One Patriot Place 
 Foxborough, MA 02035 

Attention: Bill Scalzulli 
 Novartis Institutes for Biomedical
Research, Inc. 
 250 Massachusetts Avenue 
 Cambridge, MA
02139 
 Attention: Scott Brown 
 ERP Business Holdings, LP

 515 Park Avenue, 15th Floor 

New York, NY 10022-1196 
 Attention: Elena Prokupets 

Marc Grenouilleau 
 Shore Point 25 Niger Road 

Cupecoy Sint Maarten (DWI) 
 Bruce Downey 

8120 Spring Hill Farm Drive 
 McLean, VA 22102 

Evans Investment Management, LLC 
 c/o Paul McCoy Family
Office Services 
 31 St. James Avenue, Suite 740 
 Boston, MA
02116 
 Attention: Bruce Evans 
 John Rogers 

200 West Street 
 New York, NY 10282 

 The John Rogers F.W. 2008 Family Trust 

Goldman Sachs Family Office 
 200 West Street, 40th Floor 
 New York, NY 10282 

Attn: Deborah Lehr 
 EGC4, LLC 

39 West 54th Street 
 New York, NY 10019 

Attention: Jay Eastman 
 Berenice and Michael Ronthal 

94 Beacon Street 
 Boston, MA 02108 

Susan Korsmeyer 
 207 Washington Street 

#470571 
 Brookline, MA 02447 

Rama Elluru 
 520 John Carlyle Street 

Unit 406 
 Alexandria, VA 22314 

Peter Rukeyser 
 8 Philips Lane 

Rye, NY 10580 
 Alex Williams 

96 Governor Road 
 Rochester, NY 14610 

Gus Kaloudis 
 140 East 83rd Street, #15A 
 New York, NY 10028 

Francis Rhoads 
 6596 E. Lakeridge Road 

New Market, MD 21774 
 The Paula Berliner Revocable Trust
Agreement 
 11908 Cantal Circle S 
 Parkland, FL 33076 

Attn: Deborah Reiss 
 A. Robert Zeff Revocable Trust 

200 Maple Park Blvd., Suite 208 
 St. Clair Shores, MI 48081 

Attention: Susie Zeff 

 Kenneth Anderson 

264 Weston Rd. 
 Wellesley, MA 02482 

Kenneth C. Anderson 2016 Grantor Retained Annuity Trust 

264 Weston Road 
 Wellesley, MA 02482 

Attn: Kenneth Anderson 
 Kenneth C. Anderson 2015 Irrevocable
Trust dated August 10, 2015 
 264 Weston Road 

Wellesley, MA 02482 
 Attention: David Anderson 

Cynthia Anderson 
 264 Weston Road 

Wellesley, MA 02482 
 Cynthia E. Anderson 2016 Grantor
Retained Annuity Trust 
 264 Weston Road 
 Wellesley, MA
02482 
 Attn: Cynthia Anderson 
 Cynthia E. Anderson 2015
Irrevocable Trust dated August 10, 2015 
 264 Weston Road 

Wellesley, MA 02482 
 Attention: Cynthia Anderson 

Roger K. Taylor Preservation Trust Agreement 
 60 W Broad,
Suite 300 
 Bethlehem, PA 18018 
 Attn: Jerry B. McQueen 

MC4, LLC 
 c/o Arthur Becker 

145 Spring Street, 3rd Floor 
 New York, NY 10012 

Attention: Arthur Becker 
 Miles M. Stuchin and Marcie Stuchin
JTWROS 
 400 Park Avenue, 19th Floor 
 New York, NY 10022

 Attention: Marcie Stuchin 
 Beach Trust 

400 Park Avenue, 19th Floor 

New York, NY 10022 
 Attention: Marcie Stuchin 

 Lori Alf 

1235 Marble Way 
 Boca Raton, FL 33432 

Don Brown 
 4421 McCurdy Road 

Indianapolis, IN 46234 
 Sean Dobson 2004 Grantor Retained
Annuity Trust 
 4201 Churchill Downs 
 Austin, TX 78746

 Attention: Joslyn Dobson 
 Joslyn Dobson 2004 Family
Trust 
 4201 Churchill Downs 
 Austin, TX 78746 

Attention: Joslyn Dobson 
 Stephen Brown 

5 Taylor’s Rise 
 Rochester, NY 14618 

Ronald Kirshner 
 141 Sandringham Road 

Rochester, NY 14610 
 Wakara Healthcare Investments, LLC

 C/O John Malooly 
 906 Shirecliff Road 

Salt Lake City, UT 84108 
 Attention: John Malooly 

Greg Phelps 
 75 Farley Pond Lane 

Needham, MA 02492 
 Herman and Suzanne Cohen 

3605 R Street NW 
 Washington, DC 20007 

Ronald W. Kaiser and Teresa Kaiser JTWROS 
 10 Stehle
Street 
 Annapolis, MD 21401 
 Attention: Ronald W. Kaiser 

Neil Martin and Lisa Warsinger Martin 
 7201 Loch Edin Ct.

 Potomach, MD 20854 

 C4Ever, LLC 

3299 K Street #404 
 Washington, DC 20007 

Attention: Sara Mokhtari 
 Kirk Ott 

8 Stevens Circle 
 Westwood, MA 02090 

Mike Smith 
 905 Gentlewood Street 

Gaithersburg, MD 20878 
 Carol Nakhuda 

5600 McLean Drive 
 Bethesda, MD 20814 

Schermerhorn 2012 Dynasty Trust 
 791 Crandon Blvd., #208

 Key Biscayne, FL 33149 
 Attention: Gary Schermerhorn 

Steven Allen 
 15 Woodgreen Lane 

Roslyn Heights, NY 11577 
 Amy Digeso and Paul Rakowski, Sr.

 80 Central Park West 
 Apt. 20A 

New York, NY 10023 
 Malcolm Salter 

18 Traill Street #1 
 Cambridge, MA 02138 

Alan Stone 
 3614 S Street NW 

Washington, DC 20007 
 WCS, Jr. 2012 Family Trust 

7713 Carlton Place 
 McLean, VA 22102 

Attention: Bill Sanders 
 Phil McCarty 

2 Carsha Drive 
 Natick, MA 01760 

Jason Fisherman 
 144 Cottage Street 

Brookline, MA 02445 

 Nikhil Munshi 

77 Booth Street 
 Needham, MA 02494 

Lawrence S. Wittenberg and Barbara J. Kane JTWROS 
 40
Arlo Road 
 Newton, MA 02464 
 Attention: Lawrence S.
Wittenberg 
 2014 Exchange Place Fund A, LLC 
 c/o
Goodwin Procter LLP 
 100 Northern Avenue 
 Boston, MA 02210

 Attention: David Henken 
 2014 Exchange Place Fund B, LLC

 c/o Goodwin Procter LLP 
 100 Northern Avenue 

Boston, MA 02210 Attention: David Henken 
 Gracie Partners LLC

 c/o East End Advisors LLC 
 610 Fifth Avenue, 5th Floor

 New York, NY 10020 
 Attention: Rick Solomon 

Roche Finance Ltd 
 Head, Roche Venture Fund 

Roche Finance Ltd 
 Grenzacherstrasse 124 

Bldg 21/50 
 CH-4070 Basel

 Switzerland 
 Celgene Rivot LLC 

86 Morris Avenue 
 Summit, NJ 07901 

DF Investment Partners LLC 
 55 Hudson Yards, 29th Floor 
 New York, NY 10001 

Alexander Keith Stewart 
 11748 East Bloomfield Drive 

Scottsdale, AZ 85259 
 Dharminder and Reetu Chauhan 

8 Wedgewood Road 
 Natick, MA 01760 

 Elizabeth Klein 

12 East 86th Street #15522 

New York, NY 10028 
 Evan Knisely 

1005 Turkey Run Road 
 Mclean, VA 22101 

Evan Andrew Knisely Trust u/a dtd 10/13/17 
 1005 Turkey
Run Road 
 Mclean, VA 22101 
 Attention: Evan Andrew Knisely

 Attention: Trisha Nicole Arteaga Knisely 
 Hamish
McKenzie 
 6 West Common Way 
 Harpenden 

Herts 
 AL5 2LF 

United Kingdom 
 IRA Resources, Inc. FBO: Richard Stern Press
IRA 35-35937 
 101 Bogle Street 

Weston, MA 02493 
 Lauren Talarico, as Trustee for Frank
Angelo Talarico 
 6455 Kedleston Court 
 McLean, VA 22101

 Lisa Popitz 
 PO Box 920371 

Needham, MA 02492 
 Paul Anderson 

25 Jerome Avenue 
 Auburn, MA 02501 

Pierre Rovani 
 1800 Hoban Road NW 

Washington, DC 20007 
 Robert and Gloria Fulton 

6455 Kedleston CT 
 McLean, VA 22101 

Teru Hideshima 
 72 Francis Street 

Brookline, MA 02446 

 SCHEDULE B 

Key Holders 
 Name and Address

 Dana-Farber Cancer Institute, Inc. 
 Belfer
Office for Dana-Farber Innovations 
 450 Brookline Avenue, BP304E 

Boston, MA 02215 
 Attention: Chief Research Business Development
OfficerEX-4.2

 Exhibit 4.2 

WARRANT CERTIFICATE 
 THIS
WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN
SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE SECURITIES ACT AND IS QUALIFIED UNDER APPLICABLE
STATE AND FOREIGN LAW OR (II) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE SECURITIES ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW. 

 

			
	Warrant Shares Issuable:	  	2,857,142 Shares of Series B Preferred Stock
		
	Warrant Certificate No.:	  	B-1
		
	Issue Date:	  	June 5, 2020 (the “Issue Date”)

 FOR VALUE RECEIVED, C4 Therapeutics, Inc., a Delaware corporation (the “Company”),
hereby certifies that Perceptive Credit Holdings III, LP or any of its registered assigns (collectively, the “Holder”) is entitled to purchase from the Company up to 2,857,142 duly authorized, validly issued, fully paid and
nonassessable shares of the Company’s Series B Preferred Stock at the applicable per share Exercise Price (defined below), all subject to the terms, conditions and adjustments set forth below in this Warrant Certificate. Certain capitalized
terms used herein are defined in Section 1. 
 This Warrant Certificate has been issued pursuant to the terms of
the Credit and Guaranty Agreement, dated as of June 5, 2020 (as amended or otherwise modified from time to time, the “Credit Agreement”), among the Company, as the borrower, the guarantors party thereto and Perceptive
Credit Opportunities Fund III, LP, as the lender. In connection with the execution of this Warrant Certificate, Holder shall also become a party to the Investors’ Rights Agreement as an “Investor” thereunder. For the avoidance of
doubt, shares of Common Stock issuable (directly or indirectly) upon the exercise of the Warrant shall be deemed Registrable Securities (as defined in the Investors’ Rights Agreement) before such exercise. 

Section 1. Definitions. The following terms when used herein have the following meanings: 

“Act” has the meaning set forth in Section 10(a)(i). 

“Aggregate Exercise Price” means, with respect to any exercise of this Warrant Certificate for Warrant Shares, an
amount equal to the product of (i) the number of Warrant Shares in respect of which this Warrant Certificate is then being exercised pursuant to Section 3 multiplied by (ii) the Exercise Price. 

“Assignee” has the meaning set forth in Exhibit B. 

  
 1 

 “Bloomberg” has the meaning set forth within the definition of VWAP.

 “Board” means the board of directors of the Company. 

“Business Day” means any day, except a Saturday, Sunday or legal holiday, on which banking institutions in the city of
New York, New York are authorized or obligated by law or executive order to close. 
 “Cashless Exercise” has the
meaning set forth in Section 3(b). 
 “Charter” means the Company’s Fourth Amended
and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on June 5, 2020 (as amended). 

“Common Stock” means the common stock, par value $0.0001 per share, of the Company, and any capital stock into which
such Common Stock shall have been converted, exchanged or reclassified following the date hereof. 
 “Company” has
the meaning set forth in the preamble. 
 “Credit Agreement” has the meaning set forth in the preamble. 

“DTC” means the Depository Trust Company. 

“DWAC” has the meaning set forth in Section 3(i). 

“Exercise Certificate” has the meaning set forth in Section 3(a)(i). 

“Exercise Date” means, for any given exercise of this Warrant Certificate, whether in whole or in part, the date on
which the conditions to such exercise as set forth in Section 3 shall have been satisfied at or prior to 5:00 p.m., Eastern time, on a Business Day, including, without limitation, the receipt by the Company of the
Exercise Certificate and the applicable Aggregate Exercise Price. 
 “Exercise Period” has the meaning set forth in
Section 2. 
 “Exercise Price” means a per share price equal to $1.05. 

“Fair Market Value” means, if the Warrant Shares are listed on a Trading Market, as of any particular Trading Day,
(i) the VWAP of such Warrant Shares for such day or (ii) if there have been no sales on any Trading Market on any such day, the average of the highest bid and lowest asked prices for such Warrant Shares on all applicable Trading Markets at
the end of such day. If the Warrant Shares are not listed, quoted or otherwise available for trading, the “Fair Market Value” of the Warrant Shares shall be the fair market value, per share, of such Warrant Shares as determined in
reasonable, good faith judgement of the Board (subject to the dispute mechanism set forth in Section 3(j)). 

“FAST” has the meaning set forth in Section 3(i). 

  
 2 

 “Fundamental Change” means any event or circumstance that
constitutes or results in (i) a Change in Control, as defined in the Credit Agreement (as in effect as of the date hereof) or (ii) the liquidation, bankruptcy, dissolution or winding-up (or the
occurrence of any analogous proceeding) of the Company. 
 “Holder” has the meaning set forth in the preamble. 

“Investors’ Rights Agreement” means that certain Amended and Restated Investors’ Rights Agreement by and
among the Company and certain investors party thereto dated as of June, 5, 2020, as may be amended, updated or supplemented from time to time. 

“Issue Date” has the meaning set forth in the preamble. 

“Liquidity Event” means a transaction that qualifies as a “Deemed Liquidation Event” as defined in the
Charter. 
 “Nasdaq” means The Nasdaq Stock Market, Inc. 

“OTC Bulletin Board” means the National Association of Securities Dealers, Inc. OTC Bulletin Board. 

“Person” means any individual, sole proprietorship, partnership, limited liability company, corporation, joint
venture, trust, incorporated organization or government or department or agency thereof. 
 “Prospectus” means the
prospectus or prospectuses included in any Registration Statement, as amended or supplemented by any prospectus supplement with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement
and by all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus or prospectuses. 

“Registration Statement” means any registration statement of the Company which covers any of the Registrable
Securities, including the Prospectus, amendments and supplements to such Registration Statement, including post-effective amendments, all exhibits and all materials incorporated by reference in such Registration Statement. 

“SEC” means the Securities and Exchange Commission or any successor thereto. 

“Securities Act” means the Securities Act of 1933, as amended. 

“Series B Preferred Stock” means the Series B Preferred Stock, par value $0.0005 per share, of the Company, and any
capital stock into which such Series B Preferred Stock shall have been converted, exchanged or reclassified following the date hereof. 

“Substitute Warrant Certificate” has the meaning set forth in Exhibit B. 

“Trading Day” means a day on which the principal Trading Market is open for trading. 

  
 3 

 “Trading Market” means Nasdaq or, if the Company’s equity
securities are not listed on Nasdaq, such other principal US or foreign exchange or market (including the OTC Bulletin Board) on which the Company’s equity securities issuable upon the exercise of this Warrant are quoted or available for
trading. 
 “Transfer Agent” has the meaning set forth in Section 3(c)(ii). 

“Unrestricted Conditions” has the meaning set forth in Section 10(a)(ii). 

“VWAP” means, for any security as of any day or period of days (as the case may be), the volume weighted average sale
price on Nasdaq as reported by, or based upon data reported by Bloomberg Financial Markets or an equivalent, reliable reporting service reasonably acceptable to the Holder and the Company (collectively, “Bloomberg”)
or, if Nasdaq is not the principal trading market for such security, the volume weighted average sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg or,
if no volume weighted average sale price is reported for such security by Bloomberg, then the last closing trade price of such security as reported by Bloomberg, or, if no last closing trade price is reported for such security by Bloomberg, the
average of the bid prices of any market makers for such security that are listed in the over the counter market by the Financial Industry Regulatory Authority, Inc. or on the OTC Bulletin Board (or any successor) or in the “pink sheets”
(or any successor) by the OTC Markets Group, Inc.; provided that if VWAP cannot be calculated for such security on such date in the manner provided above, the VWAP shall be the fair market value as determined jointly by the Company and the
Holder (subject to the dispute mechanism set forth in Section 3(j)). 
 “Warrant
Certificate” means this Warrant Certificate and all subsequent warrant certificates issued upon division, combination or transfer of, or in substitution for, this Warrant Certificate. 

“Warrant Register” has the meaning set forth in Section 5. 

“Warrant Shares” means the shares of Series B Preferred Stock, or other capital stock of the Company then purchasable
upon exercise of this Warrant Certificate in accordance with the terms of this Warrant Certificate. 
 Section 2. Term of
Warrant Certificate. Subject to the terms and conditions hereof, at any time or from time to time on or after the Issue Date and prior to 5:00 p.m., Eastern time, on the tenth anniversary of such date or, if such day is not a Business Day,
on the next preceding Business Day (the “Exercise Period”), the Holder of this Warrant Certificate may exercise this Warrant Certificate for all or any part of the Warrant Shares purchasable hereunder (subject to adjustment
as provided herein). 
 Section 3. Exercise of Warrant Certificate. 

(a) Exercise Procedure. This Warrant Certificate may be exercised from time to time on any Business Day during the Exercise Period, for
all or any part of the unexercised Warrant Shares, upon: 

  
 4 

 (i) delivery to the Company at its then principal executive office of an Exercise
Certificate in the form attached hereto as Exhibit A (each, an “Exercise Certificate”), duly completed (including specifying the number of Warrant Shares to be purchased) and executed; 

(ii) payment to the Company of the Aggregate Exercise Price in accordance with Section 3(b); and 

(iii) delivery to the Company of joinders to any applicable right of first refusal and co-sale
agreement, voting agreement, or other similar agreement to which the holders of Series B Preferred Stock are a party. 
 (b) Payment of
the Aggregate Exercise Price. Payment of the Aggregate Exercise Price shall be made, at the option of the Holder as expressed in the Exercise Certificate, by any of the following methods: 

(i) by delivery to the Company of a certified or official bank check payable to the order of the Company or by wire transfer of immediately
available funds to an account designated in writing by the Company, in the amount of such Aggregate Exercise Price; 
 (ii) “net
exercise” by instructing the Company to withhold a number of Warrant Shares then issuable upon exercise of this Warrant Certificate with an aggregate Fair Market Value as of the Exercise Date equal to such Aggregate Exercise Price; 

(iii) by cancellation of any debt of the Company owed to the Holder or its affiliates (including the principal amount thereof plus accrued and
unpaid interest); or 
 (iv) any combination of the foregoing. 

In the event of any withholding of Warrant Shares pursuant to Section 3(b)(ii), (iii) or (iv) (solely
to the extent of such withholding or surrender, a “Cashless Exercise”) where the number of shares whose value is equal to the Aggregate Exercise Price is not a whole number, the number of shares withheld by or surrendered to
the Company shall be rounded up to the nearest whole share and the Company shall make a cash payment to the Holder (by delivery of a certified or official bank check or by wire transfer of immediately available funds) based on the incremental
fraction of a share being so withheld by or surrendered to the Company in an amount equal to the product of (x) such incremental fraction of a share being so withheld or surrendered multiplied by (y) in the case of Series B Preferred
Stock, the Fair Market Value per Warrant Share as of the Exercise Date, and, in all other cases, the value thereof as of the Exercise Date determined in accordance with Section 3(b)(iii)(y). 

For purposes of Rule 144, to the extent permitted by applicable law, it is acknowledged and agreed that (i) the Warrant Shares
issuable upon any exercise of this Warrant Certificate in any Cashless Exercise transaction shall be deemed to have been acquired on the Issue Date, and (ii) the holding period for any Warrant Shares issuable upon the exercise of this Warrant
Certificate in any Cashless Exercise transaction shall be deemed to have commenced on the Issue Date; provided, that the Company makes no representation or warranty regarding the commencement of the holding period of any Warrant Shares. 

  
 5 

 (c) Delivery of Stock Certificates. 

(i) With respect to any exercise of this Warrant Certificate by the Holder, upon receipt by the Company of an Exercise Certificate and delivery
of the Aggregate Exercise Price (in accordance with Section 3(b)), the Company shall, within 5 Business Days, issue and deliver (or cause its Transfer Agent to issue and deliver) in accordance with the terms hereof to or
upon the order of the Holder that number Warrant Shares for the portion of this Warrant Certificate so exercised on such date, together with cash in lieu of any fraction of a share, as provided in Section 3(d). The stock
certificate or certificates so delivered shall be, to the extent possible, in such denomination or denominations as the exercising Holder shall reasonably request in the Exercise Certificate and shall be registered in the name of the Holder or,
subject to compliance with Section 6, such other Person’s name as shall be designated in the Exercise Certificate. This Warrant Certificate shall be deemed to have been exercised and such certificate or certificates of
Warrant Shares shall be deemed to have been issued, and the Holder or any other Person so designated to be named therein shall be deemed to have become a holder of record of such Warrant Shares for all purposes, as of the Exercise Date. 

(ii) If, at the time of exercise, the Company has a Transfer Agent, then upon the exercise this Warrant Certificate in whole or in part, the
Company shall, at its own cost and expense, take all necessary action, to assure that the Company’s transfer agent (the “Transfer Agent”) shall issue Warrant Shares in the name of the Holder (or its nominee) or such
other Persons as designated by the Holder (in compliance with Section 6) and in such denominations to be specified in the applicable Exercise Certificate and, if the Unrestricted Conditions are met, will not contain a
legend restricting the resale or transferability of the Warrant Shares. The Company represents and warrants that no instructions other than the foregoing instructions will be given to the Transfer Agent and that, unless waived by the Holder, this
Warrant Certificate and the Warrant Shares will be transferable in accordance with the terms of this Warrant Certificate and will not contain a legend restricting the resale or transferability of the Warrant Shares if the Unrestricted Conditions are
met. 
 (d) Fractional Shares. The Company shall not be required to issue a fractional Warrant Share upon exercise of any Warrant
Certificate. As to any fraction of a Warrant Share that the Holder would otherwise be entitled to purchase upon such exercise, the Company shall pay to such Holder an amount in cash (by delivery of a certified or official bank check or by wire
transfer of immediately available funds) equal to the product of (i) such fraction multiplied by (ii) the Fair Market Value of one Warrant Share on the Exercise Date. 

(e) Surrender of this Warrant Certificate; Delivery of New Warrant Certificate. 

(i) The Holder shall not be required to physically surrender this Warrant Certificate to the Company until the Holder has purchased all of the
Warrant Shares available hereunder and this Warrant Certificate has been exercised in full, in which case, the Holder shall, at the written request of the Company, surrender this Warrant Certificate to the Company for cancellation within
three (3) Business Days after the date the final Exercise Certificate is delivered to the Company. Partial exercises of this Warrant Certificate resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to 

 
the applicable number of Warrant Shares that have been issued hereunder as a result of previous exercises, withheld in connection with Cashless Exercises, and fractional shares for which cash was
received in lieu thereof in accordance with Section 3(d). The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Holder and any assignee, by
acceptance of this Warrant Certificate, acknowledge and agree that, by reason of the provisions of this Section 3(e), following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares
available for purchase hereunder at any given time may be less than the amount stated on the face hereof. 
 (ii) Notwithstanding the
foregoing, the Holder may request that the Company (and the Company shall), at the time of delivery of the certificate or certificates representing the Warrant Shares being issued in accordance with Section 3(c), deliver to
the Holder a new Warrant Certificate evidencing the rights of the Holder to purchase the unexpired and unexercised Warrant Shares called for by this Warrant Certificate. Unless otherwise agreed upon by the Holder in its sole discretion, such new
Warrant Certificate shall in all other respects be identical to this Warrant Certificate. 
 (f) Valid Issuance of Warrant Certificate and
Warrant Shares; Payment of Taxes. The Company hereby represents, covenants and agrees: 
 (i) This Warrant Certificate is, and any
Warrant Certificate issued in substitution for or replacement of this Warrant Certificate shall be, upon issuance, duly authorized and validly issued. 

(ii) All Warrant Shares issuable upon the exercise of this Warrant Certificate (or any substitute or replacement Warrant Certificate) pursuant
to the terms hereof shall be, upon issuance, and the Company shall take all such actions as may be necessary or appropriate in order that such Warrant Shares are, validly issued, fully paid and non-assessable,
issued without violation of any preemptive or similar rights of any stockholder of the Company and free and clear of all taxes, liens and charges. 

(iii) The Company shall take all such actions as may be necessary to ensure that all such Warrant Shares are issued without violation by the
Company of any applicable law or governmental regulation or any requirements of any Trading Market upon which shares of Series B Preferred Stock, Common Stock or other securities constituting Warrant Shares may be listed at the time of such exercise
(except for official notice of issuance which shall be immediately delivered by the Company upon each such issuance). 
 (iv) The Company
shall pay all expenses in connection with, and all taxes and other governmental charges that may be imposed on the Company with respect to, the issuance or delivery of Warrant Shares upon exercise of this Warrant Certificate. 

(v) The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant Certificate,
pursuant to the terms hereof. 

  
 7 

 (g) Conditional Exercise. Notwithstanding any other provision hereof, if an exercise
of any portion of this Warrant Certificate is to be made in connection with a public offering, a Fundamental Change or any Liquidity Event such exercise may, at the election of the Holder, be conditioned upon the consummation of such transaction, in
which case such exercise shall not be deemed to be effective until immediately prior to the consummation of such transaction. 
 (h)
Reservation of Shares. 
 (i) During the Exercise Period, the Company shall at all times reserve and keep available out of its
authorized but unissued shares of Series B Preferred Stock or other securities constituting Warrant Shares, solely for the purpose of issuance upon the exercise of this Warrant Certificate, the maximum number of Warrant Shares issuable upon the
exercise of this Warrant Certificate, and the par value per Warrant Share shall at all times be less than or equal to the Exercise Price. The Company shall not increase the par value of any Warrant Shares receivable upon the exercise of this Warrant
Certificate above the Exercise Price, and shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Series B Preferred Stock upon the exercise of
this Warrant Certificate. 
 (ii) During the Exercise Period, the Company shall at all times reserve and keep available out of its authorized
but unissued shares of Common Stock or such other securities into which the Warrant Shares may be convertible, solely for the purpose of issuance upon the conversion of the Warrant Shares, the maximum number of shares of Common Stock issuable upon
the conversion of the Warrant Shares. The Company shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock or other securities upon the
conversion of the Warrant Shares. 
 (i) Delivery of Electronic Shares. If the Company has a Transfer Agent and the Transfer Agent is
participating in the DTC Fast Automated Securities Transfer (“FAST”) program, upon written request of the Holder and in lieu of delivering physical certificates representing any shares of Series B Preferred Stock or Common
Stock (including any Warrant Shares) to be delivered under or in connection with this Warrant Certificate, the Company shall use its commercially reasonable efforts to cause the Transfer Agent to electronically transmit the such Series B Preferred
Stock or Common Stock, as the case may be, to the Holder by crediting the account of the Holder’s prime broker with the DTC through its Deposit Withdrawal Agent Commission (“DWAC”) system. The time periods for delivery
described herein shall apply to the electronic transmittals described herein. Any delivery not effected by electronic transmission shall be effected by delivery of physical certificates. 

(j) Dispute Resolution. In the case of any dispute as to the determination of Fair Market Value, any closing sales price or VWAP of the
Company’s Series B Preferred Stock or Common Stock, the arithmetic calculation of the Exercise Price or any other computation required to be made hereunder, in the event the Holder and the Company are unable to settle such dispute within five
(5) Business Days (or such longer period as the parties may agree), then either party may elect to submit the disputed matter(s) for resolution by an independent accountant, appraiser or investment bank (with relevant experience) acceptable to
the other party. Such independent party’s determination of such disputed matter(s) shall be binding upon all parties absent demonstrable error. 

  
 8 

 (k) Automatic Exercise on a Liquidity Event. If a Liquidity Event occurs with respect
to the Company at any time prior to the expiration of the Exercise Period and there remain any Warrant Shares subject to this Warrant Certificate, this Warrant Certificate shall be deemed to be automatically exercised in full for the full number of
remaining Warrant Shares, without the requirement for the delivery of an Exercise Certificate, and the Holder shall receive its pro rata share of the proceeds from such Liquidity Event as if the Warrant Shares were outstanding immediately prior to
the Liquidity Event (subject to set-off against the Aggregate Exercise Price); provided that (i) unless the giving of notice is not possible due to the circumstances of the Liquidity Event, the
Company shall give the Holder notice of any anticipated Liquidity Event as soon as practicable but in any event not less than five (5) Business Days prior to the anticipated consummation of the Liquidity Event and (ii) there shall be no
automatic exercise if the price per share to be received by the Holder for the Warrant Shares in respect of such Liquidity Event is less than the then-applicable Exercise Price and this Warrant and Holder’s right to acquire any Warrant Shares
hereunder shall terminate as of the consummation of the Liquidity Event without further consideration. 
 (l) Automatic Exercise Prior to
Expiration. If immediately prior to the expiration of the Exercise Period there remain any Warrant Shares subject to this Warrant Certificate, and as of such time, the Fair Market Value of one Warrant Share is greater than the then applicable
Exercise Price, then this Warrant Certificate shall be deemed to have been automatically exercised by the Holder, in full, immediately prior to the expiration of the Exercise Period on a Cashless Exercise basis for the full number of remaining
Warrant Shares, without the requirement for the delivery of an Exercise Certificate. 
 Section 4. Anti-Dilution
Adjustments. In order to prevent dilution of the purchase rights granted under this Warrant Certificate, the Exercise Price and the number of Warrant Shares issuable upon exercise of this Warrant Certificate shall be subject to adjustment from
time to time as provided in this Section 4 (in each case after taking into consideration any prior adjustments pursuant to this Section 4). 

(a) Anti-Dilution Rights. Anti-dilution rights applicable to the Series B Preferred Stock purchasable hereunder are as set forth in the
Charter and shall be applicable with respect to the Series B Preferred Stock issuable hereunder (including, for the avoidance of doubt, any waivers of anti-dilution adjustments with respect to the Series B Preferred Stock effected from time to time
in accordance with the terms of the Charter). For the avoidance of doubt, there shall be no duplicate anti-dilution adjustment pursuant to this Section 4 and the Charter. 

(b) Stock Dividends, Splits, Etc. At any time or from time to time after the Issue Date, if the Company declares or pays a dividend or
distribution on the outstanding shares of the Series B Preferred Stock payable in Common Stock or other securities or property (other than cash), then upon exercise of this Warrant Certificate, for each Warrant Share acquired, Holder shall receive,
without additional cost to Holder, the total number and kind of securities and/or property which Holder would have received had Holder owned the Warrant Shares of record as of the date the dividend or distribution occurred. At any time or from time
to time after the Issue Date, if the Company subdivides the outstanding shares of the Series B Preferred Stock by reclassification or otherwise into a greater number of shares, the number of Warrant Shares purchasable hereunder shall be
proportionately increased and the Exercise Price shall be 

  
 9 

 
proportionately decreased. At any time or from time to time after the Issue Date if the outstanding shares of the Series B Preferred Stock are combined or consolidated, by reclassification or
otherwise, into a lesser number of shares, the Exercise Price shall be proportionately increased and the number of Warrant Shares shall be proportionately decreased. 

(c) Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Series B
Preferred Stock are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series (including, without limitation, the conversion of the Series B Preferred Stock into Common
Stock in connection with the Company’s initial public offering and sale of its Common Stock pursuant to an effective registration statement under the Securities Act), then from and after the consummation of such event, this Warrant Certificate
will be exercisable for the number, class and series of Company securities that Holder would have received had the Warrant Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to
time in accordance with the provisions of this Warrant Certificate (without taking into account any limitations or restrictions on the exercisability of this Warrant Certificate). The Company shall make appropriate adjustment with respect to the
Holder’s rights under this Warrant Certificate to insure that the provisions of this Section 4 shall thereafter be applicable, as nearly as possible, to this Warrant Certificate in relation to any shares of stock,
securities or assets thereafter acquirable upon exercise of this Warrant Certificate. The provisions of this Section 4(c) shall similarly apply to successive reclassifications, exchanges, combinations substitutions,
replacements or other similar events. 
 (d) Conversion of Preferred Stock. In the event that all outstanding shares of the Series B
Preferred Stock are converted, automatically or by action of the holders thereof, into Common Stock pursuant to the Charter, including, without limitation, in connection with the Company’s initial, underwritten public offering and sale of its
Common Stock pursuant to an effective registration statement under the Securities Act, then from and after the date on which all outstanding shares of the Series B Preferred Stock have been so converted, this Warrant Certificate shall be exercisable
for such number of shares of Common Stock into which the Warrant Shares would have been converted had the Warrant Shares been outstanding on the date of such conversion, and the Exercise Price shall equal the Exercise Price in effect as of
immediately prior to such conversion divided by the number of shares of Common Stock into which one Warrant Share would have been converted, all subject to further adjustment thereafter from time to time in accordance with the provisions of this
Warrant Certificate. 
 (e) Certificate as to Adjustment. The Company shall, as promptly as reasonably practicable following any
adjustment of the Exercise Price or the number of Warrant Shares issuable upon exercise of this Warrant Certificate, or at any time upon written request from Holder, furnish Holder with a certificate of its Chief Executive Officer or Chief Financial
Officer stating the Exercise Price and the number of Warrant Shares for which this Warrant Certificate is exercisable, as of the effective date of such adjustment or written request a statement, including reasonable detail, of the computation of
such adjustment and the facts upon which such adjustment is based. 

  
 10 

 (f) Notices. In the event that the Company shall take a record of the holders of its
Series B Preferred Stock (or other capital stock or securities at the time issuable upon exercise of this Warrant Certificate): 
 (i) for
the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any other security or to vote at a meeting (or by written consent) to receive any right to subscribe for or purchase any shares of capital stock
of any class or any other securities; or 
 (ii) approving or enabling any capital reorganization of the Company, any reclassification of the
Series B Preferred Stock of the Company or any Fundamental Change; 
 then, and in each such case, the Company shall send or cause to be sent to the Holder
at least five (5) days prior to the applicable record date or the applicable expected effective date, as the case may be, for the event, a written notice specifying, as the case may be, (A) the record date for such dividend, distribution,
meeting or consent or other right or action, and a description of such dividend, distribution or other right or action to be taken at such meeting or by written consent, or (B) the effective date on which such Fundamental Change is proposed to
take place, and the date, if any is to be fixed, as of which the books of the Company shall close or a record shall be taken with respect to which the holders of record of Series B Preferred Stock (or such other capital stock or securities at the
time issuable upon exercise of this Warrant Certificate) shall be entitled to exchange their shares of Series B Preferred Stock (or such other capital stock or securities) for securities or other property deliverable upon such Fundamental Change,
and the amount per share and character of such exchange applicable to this Warrant Certificate and the Warrant Shares. 

Section 5. Warrant Register. The Company shall keep and properly maintain at its principal executive offices a register (the
“Warrant Register”) for all outstanding warrants issued by the Company and shall include the registration of this Warrant Certificate and any transfers thereof in such Warrant Register. The Company may deem and treat the
Person in whose name this Warrant Certificate is registered on such register as the Holder thereof for all purposes, and the Company shall not be affected by any notice to the contrary, except any assignment, division, combination or other transfer
of this Warrant Certificate effected in accordance with the provisions of this Warrant Certificate. 
 Section 6. Transfer of
Warrant Certificate. Subject to Section 10 hereof, this Warrant Certificate and all rights hereunder are transferable, in whole or in part, by the Holder without charge to the Holder, upon surrender of this Warrant
Certificate to the Company at its then principal executive offices with a properly completed and duly executed Assignment in the form attached hereto as Exhibit B, together with funds sufficient to pay any transfer taxes in
connection with the making of such transfer. Upon such compliance, surrender and delivery and, if required, such payment, the Company shall execute and deliver a new Warrant Certificate or Warrant Certificates in the name of the assignee or
assignees and in the denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant Certificate evidencing the portion of this Warrant Certificate, if any, not so assigned and this Warrant Certificate shall
promptly be cancelled. 

  
 11 

 Section 7. The Holder Not Deemed a Stockholder; Limitations on Liability.
Except as otherwise specifically provided herein, prior to the issuance to the Holder of the Warrant Shares to which the Holder is then entitled to receive upon the due exercise of this Warrant Certificate, the Holder shall not be entitled to vote
or receive dividends or be deemed the holder of shares of capital stock of the Company for any purpose, nor shall anything contained in this Warrant Certificate be construed to confer upon the Holder, as such, any of the rights of a stockholder of
the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends
or subscription rights, or otherwise. In addition, nothing contained in this Warrant Certificate shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant Certificate or otherwise) or as a
stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 7, the Company shall provide the Holder with copies of the same notices and other
information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders, including without limitation the financial information set forth in Section 3 (Information Rights) of the
Investors’ Rights Agreement and notices relating to any preemptive rights, right of first offer or tag along right set forth in the Company’s Amended and Restated Right of First Refusal and Co-Sale
Agreement, dated on or about the Issue Date (as the same may be amended). 
 Section 8. Replacement on Loss; Division and
Combination. 
 (a) Replacement of Warrant Certificate on Loss. Upon receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant Certificate and upon delivery of an indemnity reasonably satisfactory to it (it being understood that a written indemnification agreement or affidavit of loss of the Holder shall
be a sufficient indemnity) and, in case of mutilation, upon surrender of such Warrant Certificate for cancellation to the Company, the Company at its own expense shall execute and deliver to the Holder, in lieu hereof, a new Warrant Certificate of
like tenor and exercisable for an equivalent number of Warrant Shares as this Warrant Certificate so lost, stolen, mutilated or destroyed; provided that, in the case of mutilation, no indemnity shall be required if this Warrant Certificate in
identifiable form is surrendered to the Company for cancellation. 
 (b) Division and Combination of Warrant Certificate. Subject to
compliance with the applicable provisions of this Warrant Certificate as to any transfer or other assignment which may be involved in such division or combination, this Warrant Certificate may be divided or, following any such division of this
Warrant Certificate, subsequently combined with other Warrant Certificates, upon the surrender of this Warrant Certificate or Warrant Certificates to the Company at its then principal executive offices, together with a written notice specifying the
names and denominations in which new Warrant Certificates are to be issued, signed by the respective Holders or their agents or attorneys. Subject to compliance with the applicable provisions of this Warrant Certificate as to any transfer or
assignment which may be involved in such division or combination, the Company shall at its own expense execute and deliver a new Warrant Certificate or Warrant Certificates in exchange for this Warrant Certificate or Warrant Certificates so
surrendered in accordance with such notice. Such new Warrant Certificate or Warrant Certificates shall be of like tenor to the surrendered Warrant Certificate or Warrant Certificates and shall be exercisable in the aggregate for an equivalent number
of Warrant Shares as this Warrant Certificate or Warrant Certificates so surrendered in accordance with such notice. 

  
 12 

 Section 9. No Impairment. The Company shall not, by amendment of its
Charter or Bylaws, by contract, or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms to be observed or performed by it hereunder, and shall at all times in good faith assist in the carrying out of all the provisions of this Warrant Certificate and in the taking of all such action as may reasonably be requested by the Holder in
order to protect the exercise rights of the Holder against dilution or other impairment, consistent with the tenor and purpose of this Warrant Certificate. 

Section 10. Compliance with the Securities Act. 

(a) Agreement to Comply with the Securities Act, etc. 

(i) Legend. The Holder, by acceptance of this Warrant Certificate, agrees to comply in all respects with the provisions of this
Section 10 and the restrictive legend requirements set forth on the face of this Warrant Certificate and further agrees that such Holder shall not offer, sell or otherwise dispose of this Warrant Certificate or any Warrant
Shares to be issued upon exercise hereof except under circumstances that will not result in a violation of the Securities Act. Subject to clause (ii) below, this Warrant Certificate and all Warrant Shares issued upon
exercise of this Warrant Certificate (unless registered under the Securities Act) shall be stamped or imprinted with a legend in substantially the following form: 

“THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A
REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE ACT AND IS QUALIFIED UNDER APPLICABLE STATE AND FOREIGN LAW OR (II) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE ACT AND THE
QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN LAW AND, IF THE COMPANY REQUESTS, AN OPINION SATISFACTORY TO THE COMPANY TO SUCH EFFECT HAS BEEN RENDERED BY COUNSEL.” 

(ii) Removal of Restrictive Legends. Neither this Warrant Certificate nor any certificates evidencing Warrant Shares shall contain any
legend restricting the transfer thereof (including the legend set forth above in clause (i)) in any of the following circumstances: (A) while a Registration Statement covering the sale or resale of Warrant Shares is
effective under the Securities Act, (B) following any sale of this Warrant Certificate or any Warrant Shares pursuant to Rule 144, (C) if this Warrant Certificate or Warrant Shares are eligible for sale under Rule 144(b)(1), or (D) if
such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of 

  
 13 

 
the SEC) (collectively, the “Unrestricted Conditions”). The Company shall cause its counsel to issue a legal opinion, at the Company’s cost, to the Transfer Agent if
required by such Transfer Agent to effect the issuance of Warrant Shares, without a restrictive legend or removal of the legend hereunder. If the Unrestricted Conditions are met at the time of issuance of this Warrant Certificate or the Warrant
Shares, then this Warrant Certificate, Warrant Shares, as the case may be, shall be issued free of all legends. 
 (iii) Replacement
Warrant Certificate. The Company agrees that at such time as the Unrestricted Conditions have been satisfied it shall promptly (but in any event within five (5) Business Days) following written request from the Holder issue a replacement
Warrant Certificate or replacement Warrant Shares, as the case may be, free of all restrictive legends. 
 (iv) Sale of Unlegended
Shares. The Holder agrees that the removal of the restrictive legend from this Warrant Certificate and any certificates representing securities as set forth in Section 10(a)(ii) above is predicated upon the
Company’s reliance that the Holder will sell this Warrant Certificate or any such securities pursuant to either an effective Registration Statement or otherwise pursuant to the requirements of the Securities Act, including any applicable
prospectus delivery requirements, or an exemption therefrom, and that if such securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein. 

(b) Representations of the Holder. In connection with the issuance of this Warrant Certificate, the Holder specifically represents, as
of the date hereof, to the Company by acceptance of this Warrant Certificate as follows: 
 (i) The Holder is an “accredited
investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act. The Holder is acquiring this Warrant Certificate and the Warrant Shares to be issued upon exercise hereof for investment for its own account and not with a
view towards, or for resale in connection with, the public sale or distribution of this Warrant Certificate or the Warrant Shares, except pursuant to sales registered or exempted under the Securities Act. 

(ii) The Holder understands and acknowledges that this Warrant Certificate and the Warrant Shares to be issued upon exercise hereof are
“restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that, under such laws and applicable regulations, such securities may be
resold without registration under the Securities Act only in certain limited circumstances. In addition, the Holder represents that it is familiar with Rule 144 under the Securities Act, as presently in effect, and understands the resale limitations
imposed thereby and by the Securities Act. 
 (iii) The Holder acknowledges that it can bear the economic and financial risk of its
investment for an indefinite period, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in this Warrant Certificate and the Warrant Shares. The Holder has
had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant Certificate and the business, properties, prospects and financial condition of the Company. 

  
 14 

 Section 11. Representations, Warranties and Covenants of the Company. The
Company represents, warrants and covenants to the Holder that: 
 (i) the Company has the legal capacity or corporate power and authority to
enter into this Warrant Certificate and to carry out its obligations hereunder. The Company is duly organized and validly existing under the laws of its jurisdiction of organization, and the execution of this Warrant Certificate and the consummation
of the transactions contemplated herein have been duly authorized by all necessary action. No other act or proceeding, corporate or otherwise, on its part is necessary to authorize the execution of Warrant Certificate or the consummation of any of
the transactions contemplated hereby thereby. This Warrant Certificate has been duly executed by the Company and constitutes its legal, valid and binding obligation, enforceable against it in accordance with the terms of this Warrant Certificate;

 (ii) no consent, waiver, approval, authorization, exemption, registration, license or declaration is required to be made or obtained by
the Company, other than those which have been made or obtained, in connection with (i) the execution or enforceability of this Warrant Certificate or (ii) the consummation of any of the transactions contemplated hereby; 

(iii) as of the date hereof, and after giving effect to the transactions contemplated hereby, Schedule I sets forth (a) the
authorized capital stock of the Company; (b) the number of shares of capital stock issued and outstanding; (c) the number of shares of capital stock issuable pursuant to the Company’s stock plans; and (d) the number of shares of
capital stock issuable and reserved for issuance pursuant to securities exercisable for, or convertible into or exchangeable for any shares of capital stock of the Company. All of the issued and outstanding shares of capital stock of the Company
have been duly authorized and are validly issued, are fully paid and nonassessable and, except as set forth on Schedule I are not subject to any preemptive rights, rights of first refusal or similar rights, and were issued
in compliance with applicable state and federal securities laws and any rights of third parties. Except as described on Schedule I, there are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements
of any character under which the Company and any of its subsidiaries is or may be obligated to issue any equity securities of any kind and neither the Company nor any of its subsidiaries is currently in negotiations for the issuance of any equity
securities of any kind; 
 (iv) all Warrant Shares issuable and deliverable pursuant to this Warrant Certificate shall, upon issuance and the
payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the original
issuance thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue); 

  
 15 

 (v) the issuance of this Warrant Certificate shall constitute full authority to its officers
who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant Certificate; 

(vi) the Warrant Shares, when issued and paid for in accordance with the terms of this Warrant Certificate, will be issued free and clear of
all security interests, claims, liens and other encumbrances other than restrictions imposed by applicable securities laws; 
 (vii) the
Company will take all such action as may be reasonably necessary to assure that the shares constituting Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities
exchange or automated quotation system upon which the shares constituting Warrant Shares may be listed. 
 Section 12.
Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given: (a) when delivered by hand (with written confirmation of receipt); (b) when
received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission) if sent
during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient; or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage
prepaid. Such communications must be sent to the respective parties at the addresses indicated below (or at such other address for a party as shall be specified in a notice given in accordance with this Section 12). 

 

					
	If to the Company:	  	 C4 Therapeutics, Inc.
 490 Arsenal
Way, Suite 200
 Watertown, MA 02472

Attention:         Chief Executive Officer

E-mail:             mcohen.usa@gmail.com

		
	with a copy to:	    	 Goodwin Procter LLP
 100 Northern Avenue

Boston, MA 02210
 Attention: Lawrence S. Wittenberg

E-mail: LWittenberg@goodwinlaw.com

		
	If to the Holder:	  	 Perceptive Credit Holdings III, LP

c/o Perceptive Advisors LLC
 51 Astor Place, 10th Floor

New York, NY 10003
 Attention: Sandeep Dixit

E-mail:         Sandeep@perceptivelife.com

                     
PCOFReporting@perceptivelife.com

		
	with a copy to:	    	 Chapman and Cutler LLP
 1270 Avenue of the
Americas
 New York, NY 10020
 Attention: Nicholas Whitney

whitney@chapman.com

  
 16 

 Section 13. Cumulative Remedies. The rights and remedies provided in this
Warrant Certificate are cumulative and are not exclusive of, and are in addition to and not in substitution for, any other rights or remedies available at law, in equity or otherwise. 

Section 14. Equitable Relief. Each of the Company and the Holder acknowledges that a breach or threatened breach by such
party of any of its obligations under this Warrant Certificate would give rise to irreparable harm to the other party hereto for which monetary damages would not be an adequate remedy and hereby agrees that in the event of a breach or a threatened
breach by such party of any such obligations, the other party hereto shall, in addition to any and all other rights and remedies that may be available to it in respect of such breach, be entitled to equitable relief, including a restraining order,
an injunction, specific performance and any other relief that may be available from a court of competent jurisdiction. The Holder and the Company further acknowledge and agree that (i) the amount of loss or damages likely to be incurred by the
Holder as a result of the Company’s breach of any its obligations hereunder is incapable or is difficult to precisely estimate and (ii) the parties hereto are sophisticated business parties and have been represented by sophisticated and
able legal and financial counsel and negotiated this Agreement at arm’s length. 
 Section 15. Entire Agreement. This
Warrant Certificate constitutes the sole and entire agreement of the parties to this Warrant Certificate with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings and agreements, both written
and oral, with respect to such subject matter. 
 Section 16. Successor and Assigns. This Warrant Certificate and the
rights evidenced hereby shall be binding upon and shall inure to the benefit of the parties hereto and the successors of the Company and the successors and permitted assigns of the Holder. Such successors and/or permitted assigns of the Holder shall
be deemed to be a “Holder” for all purposes hereunder. 
 Section 17. No Third-Party Beneficiaries. This Warrant
Certificate is for the sole benefit of the Company and the Holder and their respective successors and, in the case of the Holder, permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person any
legal or equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Warrant Certificate. 

Section 18. Headings. The headings in this Warrant Certificate are for reference only and shall not affect the interpretation
of this Warrant Certificate. 
 Section 19. Amendment and Modification; Waiver. Except as otherwise provided herein, this
Warrant Certificate may only be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by the Company or the Holder of any of the provisions hereof shall be effective unless explicitly set forth in
writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character,
and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any rights, remedy, power or privilege arising from this Warrant Certificate shall operate or be construed as a waiver thereof; nor shall any single
or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. 

 

  
 17 

 Section 20. Severability. If any term or provision of this Warrant
Certificate is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Warrant Certificate or invalidate or render unenforceable such term or
provision in any other jurisdiction. 
 Section 21. Governing Law. This Warrant Certificate shall be governed by and
construed in accordance with the internal laws of the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of laws of
any jurisdiction other than those of the State of New York. 
 Section 22. Submission to Jurisdiction. Any legal suit,
action or proceeding arising out of or based upon this Warrant Certificate or the transactions contemplated hereby may be instituted in the federal courts of the United States of America or the courts of the State of New York in each case located in
the city of New York and county of New York, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding. Service of process, summons, notice or other document by certified or registered
mail to such party’s address set forth herein shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of
any suit, action or any proceeding in such courts and irrevocably waive and agree not to plead or claim in any such court that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. 

Section 23. Waiver of Jury Trial. EACH OF THE COMPANY AND
THE HOLDER ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE
UNDER THIS WARRANT CERTIFICATE IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY
RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY
LEGAL ACTION ARISING OUT OF OR RELATING TO THIS WARRANT CERTIFICATE
OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

Section 24. Counterparts. This Warrant Certificate may be executed in counterparts, each of which shall be deemed an original,
but all of which together shall be deemed to be one and the same agreement. A signed copy of this Warrant Certificate delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to
have the same legal effect as delivery of an original signed copy of this Warrant Certificate. 
 Section 25. No Strict
Construction. This Warrant Certificate shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. 

[SIGNATURE PAGE FOLLOWS] 

  
 18 

 IN WITNESS WHEREOF, the Company has duly executed this Warrant Certificate on the Issue Date. 

 

			
	C4 THERAPEUTICS, INC.
		
	By	 	 /s/ Marc Cohen

		 	Name: Marc Cohen
		 	Title: Chief Executive Officer

  

					
	Accepted and agreed,
	
	PERCEPTIVE CREDIT HOLDINGS III, LP
	
	By: Perceptive Credit Opportunities GP, LLC, its general partner
			
	    	 	By:	 	 /s/ Sandeep Dixit

		 	Name: Sandeep Dixit
		 	Title: Chief Credit Officer
			
		 	By:	 	 /s/ Sam Chawla

		 	Name: Sam Chawla
		 	Title: Portfolio Manager

  
 19 

 SCHEDULE I: Capitalization 

 

					
	 Type
	  	Shares	 
	 Common Stock
	  	 	10,860,000	 
	 Series Seed Preferred Stock
	  	 	4,000,000	 
	 Series A Preferred Stock
	  	 	109,145,900	 
	 Series B Preferred Stock
	  	 	138,571,428	 
	 Series B Preferred Stock Warrant
	  	 	2,857,142	 
	 Stock Plan – Common Stock
	  	 	1,569,110	 
	 Stock Plan – Options Outstanding
	  	 	8,942,156	 
	 Stock Plan – Shares Available
	  	 	32,147,089	 
	 Non-Plan – Options Outstanding
	  	 	76,712	 

  
 SCHEDULE I-1 

 Exhibit A 

to Warrant Certificate 
 FORM
OF EXERCISE CERTIFICATE 
 (To be signed only upon exercise of Warrant Certificate) 

To: ________________ 
 The undersigned, as holder
of a right to purchase shares of Series B Preferred Stock of C4 Therapeutics, Inc., a Delaware corporation (the “Company”) (or other Warrant Shares), pursuant to that certain Warrant Certificate of the Company, dated as of
June 5, 2020 and bearing Warrant Certificate No. B-1 (the “Warrant Certificate”), hereby irrevocably elects to exercise the purchase right represented by such Warrant Certificate
for, and to purchase thereunder, [________ (_____)] shares of Series B Preferred Stock of the Company and herewith makes payment of [___________ Dollars ($________)] therefor by the following method: 

(Check all that apply): 
 ______
(check if applicable) The undersigned hereby elects to make payment of the Aggregate Exercise Price of [__________ Dollars ($_______)] for [(______)] shares of Series B Preferred Stock using the method described in
Section 3(b)(i). 
 ______ (check if applicable) The undersigned hereby elects to make payment of the Aggregate
Exercise Price of [__________ Dollars ($_______)] for [(______)] shares of Series B Preferred Stock using the method described in Section 3(b)(ii). 

______ (check if applicable) The undersigned hereby elects to make payment of the Aggregate Exercise Price of [__________ Dollars ($_______)]
for [(______)] shares of Series B Preferred Stock using the method described in Section 3(b)(iii). 
 Unless
otherwise defined herein, capitalized terms have the meanings provided in the Warrant Certificate. 
 DATED: ______________ 

 

			
	PERCEPTIVE CREDIT HOLDINGS III, LP
		
	By	 	  

		 	Name:
		 	Title:

  
 A-1 

 Exhibit B 

to Warrant Certificate 
 FORM
OF ASSIGNMENT 
 THE UNDERSIGNED, Perceptive Credit Holdings III, LP, is the holder (in such capacity, the “Holder”)
of a warrant certificate issued by C4 Therapeutics, Inc., a Delaware corporation (the “Company”), bearing Warrant Certificate No. B-1 (the “Warrant
Certificate”), entitling the Holder to purchase up to 2,857,142 shares of the Company’s Series B Preferred Stock. Unless otherwise defined, capitalized terms used herein have the meanings ascribed thereto in the Warrant
Certificate. 
 FOR VALUE RECEIVED, the Holder hereby sells, assigns and transfers to [NAME OF ASSIGNEE] (the
“Assignee”) the right to acquire [all Warrant Shares entitled to be purchased upon exercise of the Warrant Certificate] [______ of the Warrant Shares entitled to be purchased upon exercise of the Warrant Certificate]. In
furtherance of the foregoing assignment, the Holder hereby irrevocably instructs the Company to (i) memorialize such assignment on the Warrant Register as required pursuant to Section 5 of the Warrant Certificate, and
(ii) pursuant to Section 6 of the Warrant Certificate, execute and deliver to the Assignee [and the Holder] a new Warrant Certificate [new Warrant Certificates] reflecting the foregoing assignment ([each] a
“Substitute Warrant Certificate”). 
 The Assignee acknowledges and agrees that its Substitute Warrant Certificate
and the Warrant Shares to be issued upon exercise thereof are being acquired for investment and that the Assignee will not offer, sell or otherwise dispose of its Substitute Warrant Certificate or any Warrant Shares to be issued upon exercise or
conversion thereof except under circumstances which will not result in a violation of the Securities Act or any applicable state securities laws. The Assignee represents and warrants for the benefit of the Company that the Assignee is an
“accredited investor” within the meaning of Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended. 

To the extent required pursuant to Section 10 of the Warrant Certificate, the Assignee acknowledges and agrees that
a restrictive legend shall be applied to the Assignee’s Substitute Warrant Certificate and the Warrant Shares issuable upon exercise of such certificate substantially consistent with the legend set forth in
Section 10(a)(i). 
 [SIGNATURE PAGE FOLLOWS] 

  
 B-1 

 
			
	PERCEPTIVE CREDIT HOLDINGS III, LP
		
	By	 	  

		 	Name:
		 	Title:

  

			
	Accepted and agreed,
	
	[NAME OF ASSIGNEE]
		
	By	 	  

		 	Name:
		 	Title:

  
 B-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]